GSK3B and lung carcinoma: Moreover, we identified glycogen synthase kinase 3 beta (GSK3B) and interleukin-6 (IL-6) as novel potential therapeutic targets in colon and lung cancers, respectively, using organoids, 3D structures derived from the CSC-like cells [13, 14].